Release Date: July 21, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Danaher Corp DHR delivered a solid second quarter with better-than-expected revenue, earnings, and cash flow.
- Life Sciences businesses had their strongest quarter in several years, with notable growth in biotechnology and diagnostics.
- The acquisition of Masimo was completed earlier than expected and is anticipated to be immediately accretive to adjusted EPS.
- Core revenue in high-growth markets increased more than 10%, with significant growth in China.
- Danaher Corp (DHR) raised its full-year adjusted EPS guidance, reflecting confidence in accelerating revenue and earnings growth.
Negative Points
- Core revenues in developed markets declined slightly due to shipment timing in biotechnology and lower respiratory revenue year-over-year.
- Bioprocessing consumables growth came in below expectations due to customer project timing and shipment delays.
- Adjusted operating profit margin decreased by 20 basis points due to lower respiratory revenue year-over-year.
- The company faces a 250 basis point year-over-year headwind from respiratory testing in the third quarter.
- Academic and government markets remain below normal levels, impacting overall growth potential.
Q & A Highlights
Q: Can you explain the revenue shortfall in the bioprocessing segment and why it won't recover in the third and fourth quarters?
A: Rainer Blair, CEO, explained that the bioprocessing business experienced delays in large chromatography resin shipments due to customer production schedule changes and site readiness challenges. These shipments, typically valued between $10 million to $30 million, were pushed out of the year. Despite this, underlying demand remains healthy, with mid-teens order growth in both consumables and equipment. Matthew Gugino, CFO, added that the impact was about $50 million to $60 million in Q2, with over $100 million shifted to next year, affecting full-year growth by a couple of hundred basis points.
Q: Is there any change in visibility or confidence in the bioprocessing pipeline given the recent shipment delays?
A: Rainer Blair, CEO, stated that the delays were concentrated around a few commercial customers and not indicative of a broad-based demand change. The company has processes in place to monitor customer inventory levels, which are currently lower than in previous years. The demand for biologic molecules remains robust, and the company does not see any change in the overall market dynamics.
Q: Are you seeing a turnaround in bioproduction equipment revenues, and what are the drivers?
A: Rainer Blair, CEO, noted that there is a positive trend in equipment revenue growth, driven by reshoring and brownfield expansion. The demand for biologic therapeutics remains strong, necessitating capacity expansion. The company is in the early stages of a multiyear CapEx cycle to support growing volumes and reshoring efforts.
Q: What is driving the increased confidence in the Life Sciences segment, particularly in consumables?
A: Rainer Blair, CEO, highlighted that biotech funding is starting to convert into spending, benefiting consumables. IDT is making progress in MRD testing, and Abcam delivered its best quarter since acquisition, with improved commercial execution and diversification into pharma and diagnostic end markets. The company is also seeing stability in academic markets.
Q: Can you provide an update on the Masimo acquisition and its performance?
A: Rainer Blair, CEO, expressed excitement about the early closure of the Masimo acquisition. The company has already launched a new 510(k) assay, and Masimo delivered high single-digit revenue growth in the first half of the year. The acquisition is expected to be immediately accretive to adjusted EPS.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
